Dr Reddy's Launches Tegoprazan in India for Acid Peptic Care

Dr Reddy's Laboratories has revealed that the India launch of Tegoprazan (50 mg) will be available shortly. It is a new generation potassium-competitive acid blocker (P-CAB) created to treat acid-related gastrointestinal disorders. The drug is for acid peptic diseases (APD), such as erosive and non-erosive gastroesophageal reflux disease (GERD), and gastric ulcers.

Tegoprazan is the solution to the problem as it come on board quickly to suppress acid release and maintains stomach pH for quite some time, thus comfort of the patient is prolonged and all therapeutic effects are manifested. The company informed that this launch is a solution to the problem existing in the country which has been growing notably over the years as acid peptic diseases is the most common cause of the illness and almost 38% of the population suffered from the problem.

A multinational clinical trial by Dr Reddy’s in India, South Africa, and Russia has shown that the treatment with Tegoprazan got the endoscopic healing of 99% of GERD patients within eight weeks.

The drug is already authorized in 21 countries including South Korea and China and is awaiting regulatory approval in other markets. US-based Phase-III trials have also been quite successful.

Also Read: Dr. Reddy Receives USFDA Notice, Expands Drug Portfolio

While talking about the release, M.V. Ramana, CEO of Branded Markets (India and Emerging Markets), Dr Reddy’s, said that Tegoprazan's entry signals the company’s dedication to taking gastrointestinal care to the next level, working well with its already strong brand portfolio like Omez, Razo, and Vono. The launch will be in collaboration with HK inno.N Corporation, the originator of Tegoprazan.

“We are sure that this novel medicine will be one of the best, if not the best, revolutions regarding GI disease and therapy in India putting it on the forefront of other diseases,” said HK inno.N CEO Dal-Won Kwak.